AC IMMUNE SA (ACIU) Stock Price, Forecast & Analysis
NASDAQ:ACIU • CH0329023102
ACIU Key Statistics, Chart & Performance
The current stock price of ACIU is 2.93 USD. In the past month the price decreased by -13.82%. In the past year, price increased by 15.35%.
ACIU Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ACIU. When comparing the yearly performance of all stocks, ACIU turns out to be only a medium performer in the overall market: it outperformed 57.45% of all stocks.
ACIU Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ACIU. ACIU has a bad profitability rating. Also its financial health evaluation is rather negative.
ACIU Financial Highlights
Over the last trailing twelve months ACIU reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS decreased by -75.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.88% | ||
| ROE | -115.1% | ||
| Debt/Equity | 0.06 |
ACIU Forecast & Estimates
10 analysts have analysed ACIU and the average price target is 9.18 USD. This implies a price increase of 213.31% is expected in the next year compared to the current price of 2.93.
For the next year, analysts expect an EPS growth of -38.62% and a revenue growth -84.04% for ACIU
ACIU Ownership
ACIU Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 397.113B | ||
| AMGN | AMGEN INC | 17.23 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.61 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACIU
Company Profile
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Company Info
AC IMMUNE SA
EPFL Innovation Park, Building B
Lausanne VAUD 1015 CH
CEO: Andrea Pfeifer
Employees: 133
Phone: 41213459121
AC IMMUNE SA / ACIU FAQ
Can you describe the business of AC IMMUNE SA?
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Can you provide the latest stock price for AC IMMUNE SA?
The current stock price of ACIU is 2.93 USD. The price decreased by -1.01% in the last trading session.
Does AC IMMUNE SA pay dividends?
ACIU does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACIU stock?
ACIU has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is ACIU stock listed?
ACIU stock is listed on the Nasdaq exchange.
What sector and industry does AC IMMUNE SA belong to?
AC IMMUNE SA (ACIU) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of ACIU stock?
AC IMMUNE SA (ACIU) has a market capitalization of 294.20M USD. This makes ACIU a Micro Cap stock.